WISPer - Idiopathic Pulmonary Fibrosis (IPF)

  • Study Sponsor and Protocol Number: 
    Mediar Therapeutics / MTX-463-I201 - WISPer
  • Specialty:
    Pulmonology
  • Type:
    Investigational Drug
  • Inclusion:
    >40 years of age
    Diagnosed with IPF within 7 years of screening for the trial
    If currently being treated with pirfenidone or nintedanib, the dose must be stable for >90 days
    If was on treatment with pirfenidone or nintedanib and the agent has been discontinued this must have occurred >30 days prior to Screening for the trial
  • Exclusion:
    Acute exacerbation of IPF within 6 months of Screening for the trial
    Requirement of continuous oxygen therapy (intermittent use during sleep or exercise is OK)
    Expected to receive a lung transplant
    Currently smoking or vaping